191 related articles for article (PubMed ID: 32793489)
21. Clinical Features and Prognosis of Diffuse Midline Glioma: A Series of 24 Cases.
Jang SW; Song SW; Kim YH; Cho YH; Hong SH; Kim JH; Ra YS; Chong S
Brain Tumor Res Treat; 2022 Oct; 10(4):255-264. PubMed ID: 36347640
[TBL] [Abstract][Full Text] [Related]
22. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
23. Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient.
Cheng R; Li DP; Zhang N; Zhang JY; Zhang D; Liu TT; Yang J; Ge M
Front Surg; 2021; 8():616334. PubMed ID: 34222313
[No Abstract] [Full Text] [Related]
24. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract][Full Text] [Related]
25. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
26. WT1 peptide immunotherapy for cancer in children and young adults.
Hashii Y; Sato E; Ohta H; Oka Y; Sugiyama H; Ozono K
Pediatr Blood Cancer; 2010 Aug; 55(2):352-5. PubMed ID: 20582983
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma.
Park C; Kim TM; Bae JM; Yun H; Kim JW; Choi SH; Lee ST; Lee JH; Park SH; Park CK
Cancer Res Treat; 2021 Apr; 53(2):389-398. PubMed ID: 33171023
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
Watanabe K; Toji S; Ohtake J; Nakano K; Satoh T; Kitamura H; Nishimura T
Biomed Res; 2013 Feb; 34(1):41-50. PubMed ID: 23428979
[TBL] [Abstract][Full Text] [Related]
30. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
Ohta H; Hashii Y; Yoneda A; Takizawa S; Kusuki S; Tokimasa S; Fukuzawa M; Tsuboi A; Murao A; Oka Y; Oji Y; Aozasa K; Nakatsuka S; Sugiyama H; Ozono K
Pediatr Hematol Oncol; 2009 Jan; 26(1):74-83. PubMed ID: 19206012
[TBL] [Abstract][Full Text] [Related]
31. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.
Shirakata T; Oka Y; Nishida S; Hosen N; Tsuboi A; Oji Y; Murao A; Tanaka H; Nakatsuka S; Inohara H; Sugiyama H
Anticancer Res; 2012 Mar; 32(3):1081-5. PubMed ID: 22399636
[TBL] [Abstract][Full Text] [Related]
32. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
33. "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.
Oka Y; Tsuboi A; Fujiki F; Shirakata T; Nishida S; Hosen N; Nakajima H; Li Z; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2008; 15(29):3052-61. PubMed ID: 19075652
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature.
Saito S; Yanagisawa R; Yoshikawa K; Higuchi Y; Koya T; Yoshizawa K; Tanaka M; Sakashita K; Kobayashi T; Kurata T; Hirabayashi K; Nakazawa Y; Shiohara M; Yonemitsu Y; Okamoto M; Sugiyama H; Koike K; Shimodaira S
Cytotherapy; 2015 Mar; 17(3):330-5. PubMed ID: 25484308
[TBL] [Abstract][Full Text] [Related]
35. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
[TBL] [Abstract][Full Text] [Related]
36. Remission of Pediatric Diffuse Intrinsic Pontine Glioma: Case Report and Review of the Literature.
Espirito Santo V; Passos J; Nzwalo H; Nunes S; Salgado D
J Pediatr Neurosci; 2021; 16(1):1-4. PubMed ID: 34316300
[TBL] [Abstract][Full Text] [Related]
37. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
38. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
